Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BATM Advanced CommunicationsBVCLF 43 3-Year EBITDA Growth Rate is 30.10% as of Dec. 2025, which is 1572% above its 10-year median of 1.80. GuruFocus rates BVCLF with a GF Score™ of 43/100. The stock has 5 warning signs investors should review. Among 692 Medical Devices & Instruments companies, BATM Advanced Communications ranks better than 77.17% on this metric.
During the past 12 months, BATM Advanced Communications's average EBITDA Per Share Growth Rate was 1550.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -24.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BATM Advanced Communications was 152.00% per year. The lowest was -66.50% per year. And the median was 1.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BATM Advanced Communications 3-Year EBITDA Growth Rate Related Terms
BVCLF vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, BATM Advanced Communications's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BATM Advanced Communications 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BATM Advanced Communications's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BATM Advanced Communications's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.10% mean?
BATM Advanced Communications (BVCLF) has a 3-Year EBITDA Growth Rate of 30.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BATM Advanced Communications and its competitors. This is 1572% above median its historical median of 1.80. According to the industry distribution chart, BATM Advanced Communications ranks #158 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 22.8%.
Is BATM Advanced Communications' 3-Year EBITDA Growth Rate too high?
BATM Advanced Communications' current 3-Year EBITDA Growth Rate of 30.10% is 1572% above median its 10-year median of 1.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. BATM Advanced Communications' value of 30.10% is 267.1% above this industry median. Based on the distribution chart, BATM Advanced Communications ranks #158 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BATM Advanced Communications has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does BATM Advanced Communications' 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, BATM Advanced Communications ranks #158 out of 692 companies for 3-Year EBITDA Growth Rate. This places BATM Advanced Communications in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. BATM Advanced Communications' value of 30.10% is 267.1% above this benchmark. While the company's 10-year median is 1.80 vs. the industry median of 8.20, BATM Advanced Communications has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BATM Advanced Communications's current 3-Year EBITDA Growth Rate of 30.10% is 267.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BATM Advanced Communications and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BATM Advanced Communications's current 3-Year EBITDA Growth Rate is 30.10%, which is 1572% above median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BATM Advanced Communications stock overvalued right now?
BATM Advanced Communications (BVCLF) has a current 3-Year EBITDA Growth Rate of 30.10%. The current 3-Year EBITDA Growth Rate is 30.10%, which is 1572% above median its 10-year median of 1.80 and 267.1% above the Medical Devices & Instruments industry median of 8.20. BATM Advanced Communications' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BATM Advanced Communications (BVCLF), the current 3-Year EBITDA Growth Rate is 30.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BATM Advanced Communications Ltd is an Israel-based technology company. It is engaged in the development, production and supply of real-time technologies and associated services in three core application areas: Networks, Cyber and Diagnostics. In addition, the Group's non-core activities comprised the production and supply of pharmaceutical applications and the distribution of third-party pharmaceutical and environmental monitoring products. The company organizes its business operations into three divisions: Networking, Cyber Division, and Diagnostics Division. It generates majority of revenue from Diagnostics mainly engaged in sales and distribution of in vitro diagnostics reagents and instruments. It operates in three geographical areas: the United States of America, Israel and Europe.
43GF Score
Get the complete analysis for BVCLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVCLF has been successfully added to your 
